Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema

Pharmacogenetics and Genomics

Volumn 20, Issue 9, 2010, Pages 532-536

  Woodard Grice, Alencia V ^a   Lucisano, Amelia C ^a   Byrd, James B ^a,b   Stone, Elizabeth R ^a   Simmons, William H ^c   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

aminopeptidase P; angioedema; angiotensin converting enzyme; XPNPEP2

Indexed keywords

AMINOPEPTIDASE P; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AFRICAN AMERICAN; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; XPNPEP2 GENE;

EID: 77955924405     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833d3acb     Document Type: Article

References (25)

1. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117:234-242.
2. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, et al. Clinical profile of angioedema associated with angiotensin-converting enzyme inhibition. JAMA 1988; 260:967-970.
3. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin-converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60:8-13.
4. Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008; 51:141-147.
5. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005; 165:1637-1642.
6. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 2006; 26:725-737.
7. Emanueli C, Grady EF, Madeddu P, Figini M, Bunnett NW, Parisi D, et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 1998; 31:1299-1304.
8. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005; 99:6-38.
9. Russell JS, Chi H, Lantry LE, Stephens RE, Ward PE. Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts. Peptides 1996; 17:1397-1403.
10. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002; 359:2088-2089.
11. Duan QL, Nikpoor B, Dube MP, Molinaro G, Meijer IA, Dion P, et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet 2005; 77:617-626.
12. Germer S, Higuchi R. Single-tube genotyping without oligonucleotide probes. Genome Res 1999; 9:72-78.
13. Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 2002; 39:460-464.
14. Stockel-Maschek A, Stiebitz B, Koelsch R, Neubert K. A continuous fluorimetric assay for aminopeptidase P detailed analysis of product inhibition. Anal Biochem 2003; 322:60-67.
15. Gibbs CR, Lip GY, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 1999; 48:861-865.
16. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens 2004; 17:103-111.
17. Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10:499-509.
18. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002; 347:621-622.
19. Cilia La Corte AL, Carter AM, Turner AJ, Grant PJ, Hooper NM. The bradykinin-degrading aminopeptidase P is increased in women taking the oral contraceptive pill. J Renin Angiotensin Aldosterone Syst 2008; 9:221-225.
20. Drouet C, Desormeaux A, Robillard J, Ponard D, Bouillet L, Martin L, et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol 2008; 121:429-433.
21. Prueitt RL, Ross JL, Zinn AR. Physical mapping of nine Xq translocation breakpoints and identification of XPNPEP2 as a premature ovarian failure candidate gene. Cytogenet Cell Genet 2000; 89:44-50.
22. Gainer JV, Nadeau JH, Ryder D, Brown NJ. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 1996; 98:283-287.
23. Campos MM, Calixto JB. Neurokinin mediation of edema and inflammation. Neuropeptides 2000; 34:314-322.
24. Coats AJS. Omapatrilat-the story of Overture and Octave. Int J Cardiology 2002; 86:1-4.
25. Van Guilder GP, Pretorius M, Luther JM, Byrd JB, Hill K, Gainer JV, et al. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension 2008; 51:454-459.